Developing Genetics-Based Personalized Dietary Guidelines for Early Management of Metabolic Syndrome Risk

Nutrigenomics approach to the regulation of body fat browning adipo-myokines for early control of metabolic syndrome risk

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011528

Enrollment

Registered

2026-01-23

Start date

2021-05-09

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(eating habit modification intervention) : At baseline, individualized daily targets for energy intake and energy expenditure were established for each participant by the principal investigator

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Participants were eligible if they were adults (=19 years of age) at the time of the visit and met at least one of the following criteria: 1) Overweight or obesity, defined as body mass index (BMI) =23 kg/m², according to the Korean Society for the Study of Obesity (KSSO) criteria; or 2) Presence of =1 metabolic syndrome (MetS) risk factor. * Metabolic Syndrome (MetS) Risk Factors MetS risk factors were defined as follows: - Fasting plasma glucose (FPG) =100 mg/dL - Waist circumference (WC): men =90 cm, women =85 cm - Blood pressure (BP): systolic BP =130 mmHg and/or diastolic BP =85 mmHg - Triglycerides (TG) =150 mg/dL - High-density lipoprotein cholesterol (HDL-C): men <40 mg/dL, women <50 mg/dL * Metabolic syndrome (MetS) is defined as the presence of three or more risk factors according to the above diagnostic criteria (NCEP–ATP III Asian-Pacific guideline, Korean Society for the Study of Obesity, and Korean Society of Lipid and Atherosclerosis).

Exclusion criteria

Exclusion criteria: Participants were excluded if they met any of the following criteria: 1) Having a diagnosed chronic disease and currently receiving treatment, including but not limited to coronary artery disease/atherosclerosis, stroke, diabetes mellitus, liver disease, or cancer. 2) Serum creatinine =3.0 mg/dL or end-stage kidney disease (ESKD). 3) Evidence of severe hepatic impairment, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =3 times the upper limit of normal (ULN). 4) Pregnant or lactating women, or women of childbearing potential. 5) Any other condition that, in the opinion of the investigator, would make the participant ineligible or inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
Metabolic syndrome risk factor (waist circumference, blood pressure, fasting glucose, HDL-cholesterol, triglyceride)	—

Secondary

Measure	Time frame
Metabolic syndrome–related risk factor levels stratified by adipo-myokine gene polymorphisms;adipokines, myokines	—

Countries

Korea, Republic of

Contacts

Public ContactOh Yoen Kim

Dong-A University

oykim@dau.ac.kr+82-51-200-7326

Outcome results